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In light of the increasing momentum towards personalised
medicine and healthcare, driven by genomic science and
a spectrum of technological and information tools [1], we
discuss the challenges and impact of personalised ap-
proaches within the UK National Health Service (NHS).
Various initiatives in the UK have attempted a shift from
population-centred to individual-centred approaches and
there have been some successful attempts to make health-
care systems more participatory and prevention-oriented.
In the UK, personalised approaches have featured on pol-
icy agendas for some time. In 2009, the House of Lords re-
port on Genomic Medicine noted that using genomics to
enable stratified use of medicines holds ‘the greatest poten-
tial for the healthcare sector’ but also presents ‘one of the
biggest translational challenges’ [2]. Stratified medicine
initiatives, co-financed by industry and government, have
encouraged the pharmaceutical industry to embrace perso-
nalised treatments and devices. In 2011, the Technology
Strategy Board published a strategic vision for making the
UK the world leader in development and adoption of strati-
fied medicine. In 2012, the potential emergence of stratified
medicine across the entire healthcare system fuelled by
genomic information was a central theme of the govern-
mental Human Genomics Strategy Group report [3].
Challenges for implementing personalised
medicine in the UK
Despite the high-level political endorsement, persona-
lised medicine remains elusive and several challenges re-
main. These include establishing a robust evidence base,
changing practice within existing health services, and fa-
cilitating an increasingly participatory approach. Some of
these challenges were analysed in the PHG Foundation
response to the Genomic Medicine report and its report
on next-generation sequencing [4,5]. The Academy of
Medical Sciences noted a further set of economic drivers
for adopting personalised approaches [6].* Correspondence: anna.pokorska-bocci@phgfoundation.org
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A personalised approach necessitates tests and interven-
tions that target increasingly finely divided subgroups re-
quiring a valid evidence base incorporating genomic
data. Genomics may contribute to personalised medicine
by allowing refined knowledge of a diagnostic group or a
subgroup characterised by its response to a treatment .
Demonstrating the clinical utility and cost-effectiveness
of expensive complex technologies in genetic diseases,
and that the replacement test is superior to existing in-
terventions in efficacy, cost-effectiveness or discrimin-
atory power, are necessary steps for implementation.
Many molecular tests have failed to satisfy these require-
ments [7].
As subgroup size diminishes, the challenge of estab-
lishing a valid evidence base will be correspondingly
greater. Yet the scale of overall knowledge generation
and its adequate storage and sharing in order to create
scientific and clinical evidence is a challenge in itself and
requires new infrastructures and processes.
Development of the evidence base is a vital part of the
translation process. Crucial to this are prospective ap-
proaches that aim to further understand the occurrence
and progression of disease and identify subgroups of pa-
tients sharing similar responses to treatments, such as
the Stratified Medicine Initiatives, and strategies devel-
oped by the UK Medical Research Council and Cancer
Research UK .
In the UK, evidence-based commissioning support for
the introduction of new technologies is provided
through National Institute for Health and Care Excel-
lence (NICE) guideline development. NICE uses metrics
such as the quality-adjusted life-years (QALY), which
combines the quality of life gained from an intervention
with the additional length of life gained. However,
current health economics practice for NHS interventions
does not include non-health outcomes, such as repro-
ductive choice and impact on family members, in the
context of genomics within QALY calculations [5]. This
is in part due to the lack of cost data or values appliedCentral Ltd. The licensee has exclusive rights to distribute this article, in any
ion. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Pokorska-Bocci et al. Genome Medicine 2014, 6:28 Page 2 of 3
http://genomemedicine.com/content/6/4/28to these outcomes. Furthermore, there are wide-ranging
methodological issues, including measuring outcomes
and effectiveness, that may require resolution before the
lack of evidence base can be addressed [8].
Refining the organisation and operation of health services
Developing integrated and increasingly sophisticated
molecular pathology and diagnostics, which are the pre-
requisites of personalised medicine, will pose challenges
for health services. Interpreting detailed and complex
findings and integrating these with phenotypic and on-
going clinical data, including outcomes, will require the
development of electronic health records. In the UK,
NHS Scotland has established an eHealth strategy to be
implemented over the next five years that aims to en-
hance integration and availability of information, im-
prove communication and enable people to be more
active participants in their healthcare [http://www.
ehealth.scot.nhs.uk/]. Patient pathways must then be de-
veloped that are technically flexible and responsive to in-
dividual patients’ needs. All this will require resources
and in this financial climate will only be achievable if
new practices are as, or more, clinically effective and
cost-effective than existing technologies.
New approaches have to be ethical and acceptable to
professionals and patients alike. The consent process will
become more dynamic and flexible and the ability of pa-
tients to make autonomous decisions increasingly im-
portant. This may require clinical guidelines to be
revised and decision support systems to be developed.
Facilitating the shift to participatory medicine
A key characteristic of personalised medicine is the para-
digm shift to the participatory healthcare model [9]. Fa-
cilitating greater awareness of available choices and
providing increased control over health management
creates novel pressures on health services and health
professionals, but also imposes new duties upon individ-
uals. Patients and the public will need to commit to the
systematic capture and sharing of clinical data to build
and fine-tune the knowledge base. This commitment will
extend both to routinely collected health data and to
sharing anonymised data through big data initiatives.
Many personalised healthcare initiatives in the UK ac-
knowledge that patients and the public should and will
be involved in designing these new, more participatory
services. The Clinical Reference Groups of NHS England
provide a good example where patients and carers be-
come stakeholders, with engagement ranging from being
kept informed to participating in consultation processes.
An increasing number of drugs and available treat-
ments will be directly linked with the patient undergoing
a diagnostic test, showing the likelihood of benefit from
that particular treatment. Increased patient participationin the management of their health brings a requirement
for health literacy, enhanced use of modern communica-
tion tools, and readiness for dialogue with medical
providers.
Impact of personalisation on public health and
the UK healthcare system
Whilst acknowledging these challenges, proponents of a
personalised agenda should be encouraged by various
developments within the UK. Personalisation may seem
to be at odds with the population-based prevention
agenda but actually the different approaches show syn-
ergy. UK prevention programmes such as healthy eating
or reduction of tobacco consumption assume that the
population is homogeneous and interventions that re-
duce the average risk will have a major effect. The com-
plementary approach involves identification of a high-
risk group for special preventive interventions. This
principle is embedded in the UK NHS Health Check
programme, for example, which uses conventional risk
factors such as age, sex, body mass index, smoking sta-
tus, and a range of physiological measurements to iden-
tify people requiring intensive preventive management.
Addition of genetic biomarkers enables this approach to
further fine-tune risk estimation. Risk can be stratified at
an early age and across the whole risk spectrum [10]. In-
dividuals who are low risk are not potentially harmed by
preventive interventions and resources are targeted more
efficiently.
Introducing genomics into population-based preven-
tion programmes will not be simple. It will be important
to ensure that individuals are not unduly worried by
their risk status or confused by differential prevention
advice, that those at high risk are not stigmatised by em-
ployers or insurers, and that people trust the systems
that will handle their genetic information. Integral to the
introduction of many aspects of personalised prevention
in the UK will be involvement of the National Screening
Committee, the body that advises ministers and the
NHS in all four countries about all aspects of screening
and supports the implementation of screening pro-
grammes. In particular, the Committee will need to ad-
dress the principle of two-stage screening, where the
first step involves determination of individual risk, based
on biomarkers, family history and physiological meas-
urement, before progressing to application of the screen-
ing intervention. Such a step involves a paradigm shift
from the concept of screening programmes applied on
an equal basis to large populations.
The UK 100,000 Genomes Project [http://www.geno
micsengland.co.uk/100k-genome-project/] is a major ini-
tiative that will promote personalised medicine in the
UK by providing a mechanism for developing new diag-
nostics and treatments, and explicitly linking these to
Pokorska-Bocci et al. Genome Medicine 2014, 6:28 Page 3 of 3
http://genomemedicine.com/content/6/4/28clinical care. An important aspect of this has been the
setting up of a strategic group under Health Education
England that will take the lead in preparing the NHS
workforce for the introduction of genomics. By engaging
with all key stakeholders, including the public, this pro-
ject has the potential to catalyse a system change.
Conclusions
A plethora of scientific, technological and communication
tools open new possibilities to improve healthcare by fine-
tuning health management to individuals’ needs and pref-
erences. However, a lot of work has still to be done to
ensure that populations and individuals fully benefit from
this new era. Health professionals, policy makers and
other stakeholders need to work together to develop
health services and involve patients and the public in the
personalised medicine endeavour.
Establishing the evidence base and demonstrating the
clinical utility of new tests or treatments will be crucial.
Systematic use of electronic health records, employment
of various methods to encourage participation of pa-
tients and clinicians in decision-making, and collection
and sharing of health data will be prerequisites. Finally,
we also note the importance of personalisation in the
public health prevention agenda.
Abbreviations
NHS: National Health Service; NICE: National Institute for Health and Care
Excellence; QALY: quality-adjusted life-years.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
The authors thank Alison Stewart for contributing to the intellectual content
of the manuscript.
References
1. Pokorska-Bocci A, Stewart A, Sagoo GS, Hall A, Kroese M, Burton H:
Personalised medicine: What’s in a name? Pers Med, in press.
2. House of Lords (2009) Genomic Medicine. Her Majesty’s Stationery Office,
London
3. The Human Genomics Strategy Group (2012) Building on our Inheritance:
Genomic Technology in Healthcare. Department of Health, London
4. Foundation PHG (2010) Genomic Medicine: An Independent Response to
the House of Lords Science and Technology Committee Report. Cambridge,
UK, PHG Foundation
5. Wright C, Burton H, Hall A, Moorthie S, Pokorska-Bocci A, Sagoo GS,
Sanderson S, Skinner R (2011) Next Steps in the Sequence: The
Implications of Whole Genome Sequencing for Health in the UK.
Cambridge, UK, PHG Foundation
6. The Academy of Medical Sciences (2007) Optimizing Stratified Medicines
R&D: Addressing Scientific and Economic Issues. The Academy of Medical
Sciences, London
7. Evaluation of Genomic Applications in Practice and Prevention Working
Group (2013) The EGAPP initiative: lessons learned. Gen Med 16:217–224
Published: 2 April 201458. Buchanan J, Wordsworth S, Schuh A (2013) Issues surrounding the health
economic evaluation of genomic technologies. Pharmacogenomics
14:1833–1847
9. Hood L (2008) A personal journey of discovery: developing technology and
changing biology. Annu Rev Anal Chem 1:1–43
10. Burton H, Chowdhury S, Dent T, Hall A, Pashayan N, Pharoah P (2013) Public
health implications from COGS and potential for risk stratification and
screening. Nat Genet 45:349–351
doi:10.1186/gm545
Cite this article as: Pokorska-Bocci et al.: Personalised medicine in the
UK: challenges of implementation and impact on healthcare system.
Genome Medicine 2014 6:28.
